Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 1
2020 4
2021 8
2022 4
2024 7
2025 11

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study.
Siriratnam P, Sanfilippo P, van der Walt A, Sharmin S, Foong YC, Yeh WZ, Zhu C, Khoury SJ, Csepany T, Willekens B, Etemadifar M, Ozakbas S, Nytrova P, Altintas A, Al-Asmi A, Yamout B, Laureys G, Patti F, Simo M, Surcinelli A, Foschi M, McCombe PA, Alroughani R, Sánchez-Menoyo JL, Turkoglu R, Soysal A, Lechner Scott J, Kalincik T, Butzkueven H, Jokubaitis V, Huda S, Monif M; MSBASE study group. Siriratnam P, et al. Among authors: surcinelli a. J Neurol Neurosurg Psychiatry. 2025 Mar 24;96(4):361-369. doi: 10.1136/jnnp-2024-334090. J Neurol Neurosurg Psychiatry. 2025. PMID: 39231582
Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis.
Müller J, Sharmin S, Lorscheider J, Ozakbas S, Karabudak R, Horakova D, Weinstock-Guttman B, Shaygannejad V, Etemadifar M, Alroughani R, Patti F, Eichau S, Prat A, Lugaresi A, Tomassini V, Kermode AG, Amato MP, Turkoglu R, Altintas A, Buzzard K, Soysal A, van der Walt A, Butzkueven H, Blanco Y, Gerlach O, Khoury SJ, Barnett M, John N, Lechner-Scott J, Foschi M, Surcinelli A, van Pesch V, Prevost J, Sa MJ, Maimone D, D'hooghe M, Hughes S, Hodgkinson S, McGuigan C, Cartechini E, Taylor B, Spitaleri D, Slee M, McCombe P, Yamout B, Benkert P, Kuhle J, Kappos L, Roos I, Kalincik T; MSBase Study Group; Havrdova EK, Girard M, Duquette P, Fabis-Pedrini M, Carroll WM, Skibina O, Gouider R, Mrabet S, Ramo-Tello C, Solaro C, Habek M, Van Wijmeersch B, Ampapa R, Macdonell R, Oreja-Guevara C, de Gans K, Laureys G, Oh J, Garber J, Gray O, Agüera-Morales E, Sanchez-Menoyo JL, Castillo-Triviño T, Grigoriadis N, Petersen T, Hardy TA, Vucic S, Reddel S, Ramanathan S, Al-Asmi A, Simu M, Baghbanian SM, Poehlau D, Al-Harbi T, Rojas JI, Deri N, Lalive P, Cambron M, Csepany T, Shuey N, Willekens B, Shaw C, Decoo D, Massey J, Yaldizli Ö, Derfuss T, Granziera C. Müller J, et al. Among authors: surcinelli a. JAMA Neurol. 2025 Jun 1;82(6):614-625. doi: 10.1001/jamaneurol.2025.0495. JAMA Neurol. 2025. PMID: 40227706
Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries.
Sharmin S, Roos I, Malpas CB, Iaffaldano P, Simone M, Filippi M, Kubala Havrdova E, Ozakbas S, Brescia Morra V, Alroughani R, Zaffaroni M, Patti F, Eichau S, Salemi G, Di Sapio A, Inglese M, Portaccio E, Trojano M, Amato MP, Kalincik T; Writing Group; Italian Multiple Sclerosis and Related Disorders Register and MSBase Study Group. Sharmin S, et al. Lancet Child Adolesc Health. 2024 May;8(5):348-357. doi: 10.1016/S2352-4642(24)00047-6. Epub 2024 Mar 25. Lancet Child Adolesc Health. 2024. PMID: 38547883
A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic.
Lal AP, Foong YC, Sanfilippo PG, Spelman T, Rath L, Levitz D, Fabis-Pedrini M, Foschi M, Habek M, Kalincik T, Roos I, Lechner-Scott J, John N, Soysal A, D'Amico E, Gouider R, Mrabet S, Gross-Paju K, Cárdenas-Robledo S, Moghadasi AN, Sa MJ, Gray O, Oh J, Reddel S, Ramanathan S, Al-Harbi T, Altintas A, Hardy TA, Ozakbas S, Alroughani R, Kermode AG, Surcinelli A, Laureys G, Eichau S, Prat A, Girard M, Duquette P, Hodgkinson S, Ramo-Tello C, Maimone D, McCombe P, Spitaleri D, Sanchez-Menoyo JL, Yetkin MF, Baghbanian SM, Karabudak R, Al-Asmi A, Jakob GB, Khoury SJ, Etemadifar M, van Pesch V, Buzzard K, Taylor B, Butzkueven H, Van der Walt A. Lal AP, et al. Among authors: surcinelli a. J Neurol. 2024 Sep;271(9):5813-5824. doi: 10.1007/s00415-024-12518-7. Epub 2024 Jun 27. J Neurol. 2024. PMID: 38935148 Free PMC article.
Hypogammaglobulinemia and severe infections in Multiple Sclerosis patients on anti-CD20 agents: A multicentre study.
Smolik K, Camilli F, Panzera I, Fiore A, Franceschini A, Foschi M, Surcinelli A, Pesci I, Ferri C, Bazzurri V, Mancinelli L, Zini C, Simone AM, Lugaresi A, Falzone F, Granella F, Piscaglia MG, Guareschi A, Baldi E, Immovilli P, Montepietra S, Santangelo M, Poma N, Cardi M, De Napoli G, Vitetta F, Ferraro D. Smolik K, et al. Among authors: surcinelli a. Mult Scler Relat Disord. 2025 Jan;93:106191. doi: 10.1016/j.msard.2024.106191. Epub 2024 Nov 24. Mult Scler Relat Disord. 2025. PMID: 39616774 Free article.
The impact of COVID-19 infection on multiple sclerosis disease course across 12 countries: a propensity-score-matched cohort study.
Levitz D, Chao Foong Y, Sanfilippo P, Spelman T, Rath L, Roldan A, Lal A, Monif M, Jokubaitis V, Ozakbas S, Alroughani R, Boz C, Terzi M, Kalincik T, Blanco Y, Foschi M, Surcinelli A, Buzzard K, Skibina O, Laureys G, Van Hijfte L, Ramo-Tello C, Soysal A, Sanchez-Menoyo JL, Habek M, Cartechini E, Rojas JI, Karabudak R, Willekens B, Al-Harbi T, Fragoso Y, Castillo-Triviño T, Decoo D, Aragon de Vecino MC, Skromne E, Sirbu CA, Zhu C, Merlo D, Gresle M, Butzkueven H, Van Der Walt A. Levitz D, et al. Among authors: surcinelli a. Ther Adv Neurol Disord. 2024 Nov 7;17:17562864241278496. doi: 10.1177/17562864241278496. eCollection 2024. Ther Adv Neurol Disord. 2024. PMID: 39525878 Free PMC article.
Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis.
Kalincik T, Sharmin S, Roos I, Freedman MS, Atkins H, Massey J, Sutton I, Withers B, Burman J, Torkildsen Ø, Bø L, Lehmann AK, Havrdova EK, Krasulova E, Trneny M, Kozak T, Macdonell R, Brown JWL, Coles A, van der Walt A, Butzkueven H, Van Wijmeersch B, Lechner-Scott J, Barnett M, Laureys G, Willekens B, Buzzard K, Skibina O, Di Gregorio M, Hodgkinson S, Ozakbas S, Meca-Lallana JE, Alroughani R, Prevost J, Foschi M, Surcinelli A, Neri S, Eichau S, McCombe P, John N, Cárdenas-Robledo S, Oh J, Sanchez-Menoyo JL, Patti F, Gerlach O, Blanco Y, Grammond P, Sharrack B, Snowden JA. Kalincik T, et al. Among authors: surcinelli a. Brain. 2025 Aug 4:awaf286. doi: 10.1093/brain/awaf286. Online ahead of print. Brain. 2025. PMID: 40755195 Free article.
First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis.
Toscano S, Spelman T, Ozakbas S, Alroughani R, Chisari CG, Lo Fermo S, Prat A, Girard M, Duquette P, Izquierdo G, Eichau S, Grammond P, Boz C, Kalincik T, Blanco Y, Buzzard K, Skibina O, Sa MJ, van der Walt A, Butzkueven H, Terzi M, Gerlach O, Grand'Maison F, Foschi M, Surcinelli A, Barnett M, Lugaresi A, Onofrj M, Yamout B, Khoury SJ, Prevost J, Lechner-Scott J, Maimone D, Amato MP, Spitaleri D, Van Pesch V, Macdonell R, Cartechini E, de Gans K, Slee M, Castillo-Triviño T, Soysal A, Sanchez-Menoyo JL, Laureys G, Van Hijfte L, McCombe P, Altintas A, Weinstock-Guttman B, Aguera-Morales E, Etemadifar M, Ramo-Tello C, John N, Turkoglu R, Hodgkinson S, Besora S, Van Wijmeersch B, Fernandez-Bolaños R, Patti F; MSBase Study Group. Toscano S, et al. Among authors: surcinelli a. Neurotherapeutics. 2025 Mar;22(2):e00552. doi: 10.1016/j.neurot.2025.e00552. Epub 2025 Feb 17. Neurotherapeutics. 2025. PMID: 39965993 Free PMC article.
Persistent progression independent of relapse activity in multiple sclerosis.
Zhu C, Zhou Z, Kalincik T, Roos I, Buzzard K, Skibina O, Alroughani R, Kuhle J, Girard M, Grammond P, Lechner-Scott J, Gerlach O, John N, McCombe P, Macdonell R, van Pesch V, Laureys G, Prevost J, Horakova D, Kubala Havrdova E, Castillo-Triviño T, Ramo-Tello C, Blanco Y, Meca-Lallana JE, Lugaresi A, Tomassini V, Cartechini E, Amato MP, Spitaleri D, Patti F, Maimone D, Foschi M, Surcinelli A, D'Amico E, Yamout B, Khoury SJ, Jose Sa M, Boz C, Ozakbas S, Weinstock-Guttman B, Merlo D, Monif M, Jokubaitis VG, van der Walt A, Butzkueven H. Zhu C, et al. Among authors: surcinelli a. Brain Commun. 2025 Aug 21;7(5):fcaf306. doi: 10.1093/braincomms/fcaf306. eCollection 2025. Brain Commun. 2025. PMID: 40909095 Free PMC article.
NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or Natalizumab.
Signoriello E, Signori A, Lus G, Romano G, Marfia GA, Landi D, Napoli F, D' Amico E, Zanghí A, Di Filippo PS, Caliendo D, Carotenuto A, Spiezia AL, Fantozzi R, Centonze D, Lucchini M, Mirabella M, Cocco E, Frau J, Maniscalco GT, Di Battista ME, Foschi M, Surcinelli A, Bonavita S, Abbadessa G, Pasquali L, Di Gregorio M, Ferrò MT, Sormani MP, Schiavetti I; ON focus study group. Signoriello E, et al. Among authors: surcinelli a. Mult Scler Relat Disord. 2024 Jul;87:105594. doi: 10.1016/j.msard.2024.105594. Epub 2024 Apr 6. Mult Scler Relat Disord. 2024. PMID: 38718748 Free article.
32 results